

Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release

Jeong A Park ¹, Brian H Santich,¹ Hong Xu,¹ Lawrence G Lum,² Nai-Kong V Cheung ¹

To cite: Park JA, Santich BH, Xu H, *et al.* Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release.

Journal for ImmunoTherapy of Cancer 2021;**9**:e002222. doi:10.1136/jitc-2020-002222

► Additional material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/jitc-2020-002222>).

Accepted 17 March 2021



© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA

²Medicine, University of Virginia, Charlottesville, Virginia, USA

Correspondence to
Dr Nai-Kong V Cheung;
cheungn@mskcc.org

ABSTRACT

Background T cell-based immunotherapies using chimeric antigen receptors (CAR) or bispecific antibodies (BsAb) have produced impressive responses in hematological malignancies. However, major hurdles remained, including cytokine release syndrome, neurotoxicity, on-target off-tumor effects, reliance on autologous T cells, and failure in most solid tumors. BsAb armed T cells offer a safe alternative.

Methods We generated ex vivo armed T cells (EATs) using IgG-[L]-scFv-platformed BsAb, where the anti-CD3 (huOKT3) scFv was attached to the light chain of a tumor-binding IgG. BsAb density on EAT, in vitro cytotoxicity, cytokine release, in vivo trafficking into tumors, and their antitumor activities were evaluated in multiple cancer cell lines and patient-derived xenograft mouse models. The efficacy of EATs after cryopreservation was studied, and gamma delta ($\gamma\delta$) T cells were investigated as unrelated alternative effector T cells.

Results The antitumor potency of BsAb armed T cells was substantially improved using the IgG-[L]-scFv BsAb platform. When compared with separate BsAb and T cell injection, EATs released less TNF- α , and infiltrated tumors faster, while achieving robust antitumor responses. The in vivo potency of EAT therapy depended on BsAb dose for arming, EAT cell number per injection, total number of EAT doses, and treatment schedule intensity. The antitumor efficacy of EATs was preserved following cryopreservation, and EATs using $\gamma\delta$ T cells were safe and as effective as $\alpha\beta$ T cell-EATs.

Conclusions EATs exerted potent antitumor activities against a broad spectrum of human cancer targets with remarkable safety. The antitumor potency of EATs depended on BsAb dose, cell number and total dose, and schedule. EATs were equally effective after cryopreservation, and the feasibility of third-party $\gamma\delta$ -EATs offered an alternative for autologous T cell sources.

INTRODUCTION

T cell-based immunotherapy using chimeric antigen receptor (CAR), immune checkpoint inhibitors, or T cell-engaging bispecific antibody (T-BsAb) has shown major responses in human cancers, including metastatic stage or relapsed disease.^{1–4} However, clinical success

has been limited to hematological malignancies and a few solid cancers with high tumor mutational burden. The immune suppressive tumor microenvironment (TME), cytokine release syndrome (CRS), life-threatening neurotoxicity, and permanent on-target off-tumor side effects are persisting immunological hurdles.^{5–8}

Beyond CAR T cells, BsAb armed T cells have been investigated clinically.^{9–11} Using chemically conjugated anti-GD2 \times anti-CD3 (hu3F8 \times mouse OKT3; NCT02173093), anti-HER2 \times anti-CD3 (trastuzumab \times mouse OKT3; NCT00027807), and anti-EGFR \times anti-CD3 (cetuximab \times mouse OKT3; NCT04137536), BsAb armed T cells have been administered safely with minimal neurotoxicities or cytokine storm. They were safe at cell doses as high as 4×10^{10} /dose in more than 170 patients in breast, prostate, and pancreatic cancers, as well as in hematological malignancies.^{9–11–13} However, robust responses remained elusive due to insufficient T cell infiltration and persistence, and/or impaired T cell function in the TME.

We previously demonstrated that the interdomain distance and cis-configuration of BsAb are critical for in vivo antitumor response.¹⁴ We take advantage of our structural design strategy for BsAb armed T cell. We generate ex vivo IgG-[L]-scFv-platformed BsAb armed T cells (EATs) and test their efficacy. First, we show that altering BsAb structural format significantly affects BsAb armed T cell infiltration into tumors and in vivo antitumor response, as expected by the relationship between tumor infiltrating lymphocyte (TIL) density and clinical outcome.^{15–16} Second, using EATs, we investigate the optimal surface density of BsAb, cytokine release, and in vivo T cell trafficking into tumors and persistence. Third, we study

the factors determining the antitumor efficacy of EAT therapy. Fourth, we test the stability and efficacy of EATs after cryopreservation. Finally, we evaluate gamma delta T cells ($\gamma\delta$ T cells) for EAT therapy as an off-the-shelf unrelated T cells that should avoid or minimize graft-versus-host disease.

METHODS

T cell expansion ex vivo

Serially expanded T cells from a single donor were used for each individual experiment. Peripheral blood mononuclear cells (PBMCs) were separated from buffy coats (New York Blood Center) by Ficoll. Naïve T cells were purified using Pan T Cell Isolation Kit (Miltenyi Biotec, Cat#130096535) and expanded by CD3/CD28 Dynabeads (Gibco, Cat#11132D) for 7–14 days in the presence of 30 IU/mL of interleukin-2 (IL-2). Expanded T cells were analyzed for their proportion of CD3(+), CD4(+), and CD8(+) T cells, and the fraction of CD4 or CD8 T cells was allowed between 40% and 60% to maintain consistency. Unless stated otherwise, these activated T cells were used for all T cell experiments.

Autologous T cell activation

Naïve T cells were separated from cryopreserved peripheral blood stem cell collections with institutional review board (IRB) approval. These cells were purified using Dynabeads untouched human T cell kit (Invitrogen, Cat# 11344D) and expanded with CD3/CD28 Dynabeads (Gibco, Cat#11132D) and 30 IU/mL of IL-2 for 10–14 days.

Gamma delta T cell activation

$\gamma\delta$ T cells were expanded in one of two ways: (1) fresh PBMCs separated from buffy coats were cultured with 2 μ M of zoledronic acid (Sigma, #Cat 165800066) and 800 IU/mL of IL-2 for 12–14 days according to protocols; and (2) fresh PBMCs were cultured with 2 μ M of zoledronic acid and 30 ng/mL of IL15R α -IL15 for 12–14 days. Cultured PBMCs were tested for their antigen expression using antibodies against human CD3 (BioLegend, Cat# 300308, RRID:AB_314044), CD4 (BioLegend, Cat# 357410, RRID:AB_2565662), CD8 (BioLegend, Cat# 300912, RRID:AB_314116), $\gamma\delta$ T cell receptor (TCR) (BioLegend, Cat# 331207, RRID:AB_1575111), and $\alpha\beta$ TCR (BioLegend, Cat# 306723, RRID:AB_2563001). The IL15R α -IL15 complex was prepared as described.¹⁷

Tumor cell lines

Representative neuroblastoma cell line IMR-32 (ATCC-CCL-127), osteosarcoma cell line 143B (ATCC-CRL-8303) and U-2 OS (ATCC-HTB-96), primitive neuroectodermal tumor cell line TC-71 (ATCC-CRL-1598), prostate cancer cell line LNCaP-AR (ATCC-CRL-1740), and melanoma cell line M14 (UCLA-SO-M14) were used. All cancer cells were authenticated by short tandem repeats profiling using PowerPlex V.2.1

System (Promega, Cat# DC8942) and periodically tested for mycoplasma infection using a commercial kit (Lonza, Cat# LT07-318). The luciferase-labeled melanoma cell line M14Luc, osteosarcoma cell line 143BLuc, and neuroblastoma cell line IMR32Luc were generated by retroviral infection with an SFG-GF Luc vector.

GD2-BsAb or HER2-BsAb was mainly used for arming T cells. Hu3F8-BsAb specific for GD2 was built on the IgG-[L]-scFv format, in which the anti-CD3 huOKT3 single-chain variable fragment (ScFv) was linked to the carboxyl end of the anti-GD2 hu3F8 IgG1 light chain, where the N297A mutation was introduced to remove glycosylation and the K322A to remove complement activation—a combination to reduce spontaneous cytokine release.¹⁸ HER2-BsAb built on the IgG-[L]-scFv format carried a heavy chain variable (VH) identical to that of trastuzumab IgG1, again with both N297A and K322A mutations to silence fragment crystallisable (Fc) functions.¹⁹ Hu3F8 \times mOKT3 and Herceptin \times mOKT3 chemical conjugates were made as previously described by Sen *et al.*^{10,20} The other BsAbs were synthesized as previously described (US Patent #62/896415).^{18,21–23} Anti-CD33/anti-CD3 BsAb or anti-GPA33/anti-CD3 BsAb was used as a control BsAb.²² Biochemistry data of these BsAbs are summarized in online supplemental table 1.

Antibody-dependent T cell-mediated cytotoxicity

T cell-mediated cytotoxicity was performed using ⁵¹Cr release,¹⁸ and EC₅₀ was calculated using SigmaPlot software. Target cells were labeled with sodium ⁵¹Cr chromate (⁵¹CrNa₂CrO₄; Amersham, Arlington Heights, Illinois) at 100 μ Ci/10⁶ cells at 37°C for 1 hour. After washing twice, these radiolabeled target cells were plated in 96-well plates. BsAb armed T cells were added to target cells at decreasing effector to target cell (E:T) ratios, at twofold dilutions from 50:1. After incubation at 37°C for 4 hours, the released ⁵¹Cr was measured by a gamma counter (Packed Instrument, Downers Grove, Illinois). The percentage of specific lysis was calculated using the formula where cpm represented counts per minute of ⁵¹Cr released.

$$\frac{100\% \times (\text{experimental cpm} - \text{background cpm})}{(\text{total cpm} - \text{background cpm})}$$

Total release of ⁵¹Cr was assessed by lysis with 10% sodium dodecyl sulfate (SDS; Sigma, St Louis, Missouri, Cat# 71736) and background release was measured in the absence of effector cells and antibodies.

Cytokine release assays

Human T helper 1 (Th1) cell-released cytokines including IL-2, IL-6, IL-10, interferon (IFN)- γ and tumor necrosis factor (TNF)- α were measured using LEGENDplex Human Th1 Panel (BioLegend, Cat# 741035) in vitro and in vivo and analyzed by flow cytometry.

T cell arming

Activated T cells were armed with each BsAb for 20 min at room temperature and washed twice with

phosphate-buffered saline (PBS). T cell surface BsAb density was measured by mean fluorescence intensity (MFI) using anti-idiotypic antibody or anti-human IgG Fc antibody (BioLegend, Cat# 409303, RRID:AB_10900424). MFIs were referenced to antibody binding capacity using Quantum Simply Cellular microspheres (Bio-Rad, Cat# FCSC815A, RRID:AB_10061915).

Freeze-thaw of EATs

After arming, EATs were centrifuged at 500 g for 5 min at 4°C, and the cell pellet was suspended in T cell freezing medium (90% of fetal bovine serum (FBS) and 10% dimethyl sulfoxide (DMSO)) to achieve a cell concentration of 5×10^7 cells/1 mL, chilled to 4°C and aliquoted into 2 mL cryovials. Vials were immediately transferred to freeze at -80°C for 24 hours before transferring to liquid nitrogen. After storage cryovials were thawed in a 37°C water bath with gentle swirling for 1 min. The thawed cells were transferred to F10 media and centrifuged at 500 g for 5 min. They were analyzed for viability, phenotype, antibody binding, and cytotoxicity.

T cell transduction with tdTomato and click beetle red luciferase

T cells isolated from PBMCs were stimulated with CD3/CD28 Dynabeads (Gibco, Cat#11132D) for 24 hours. T cells were transduced with retroviral constructs containing tdTomato and click beetle red luciferase in RetroNectin (Takara Bio, #Cat T100A/B)-coated six-well plates in the presence of IL-2 (100 IU/mL) and protamine sulfate (4 µg/mL). Transduced T cells were cultured for 8 days before use in animal experiments.

In vivo antitumor effects

Tumor cells suspended in Matrigel (Corning, Tewksbury, Massachusetts) were implanted in the flank of male BALB-*Rag2*^{-/-}IL-2R γ c-KO (BRG) mice aged 6–10 weeks old (Taconic Biosciences).²⁴ The following tumor cell lines were used: 1×10^6 of 143BLuc, 5×10^6 of IMR32Luc, 5×10^6 of M14Luc, 5×10^6 of HCC1954, 5×10^6 of LnCaP-AR, and 5×10^6 TC-71. Three osteosarcoma, two neuroblastoma, one Ewing sarcoma, and one breast cancer patient-derived tumor xenografts (PDXs) established from fresh surgical specimens with Memorial Sloan Kettering Cancer Center (MSKCC) IRB approval were used for in vivo experiments (online supplemental table 2). Treatment was initiated after tumors were established, with an average tumor volume of 100 mm³ when measured using TM900 scanner (Piera, Brussels, Belgium). Before treatment, mice were randomly assigned to each group. The T cell number administered per dose was 2×10^7 cells based on previous reports.²⁵ When tumor growth reached 2000 mm³ or greater, mice were euthanized. CBC analyses, body weight, general activity, physical appearance and graft-versus-host-disease (GVHD) scoring were monitored. All animal experiments were repeated twice more with different donor's T cells to ensure that our results were reliable.

Bioluminescence imaging

Luc(+) T cell engraftment and trafficking were quantified after intravenous injection of 3 mg D-luciferin (Gold Biotechnology, Cat# LUCK-100) on different days following T cell injection. Bioluminescence images were acquired using IVIS Spectrum CT In Vivo Imaging System (Caliper Life Sciences) and overlaid onto visible light images, to allow Living Image V.2.60 (Xenogen) to quantify bioluminescence in the tumor regions of interest (ROI). The total flux (photon/s) in the ROI was monitored.

Flow cytometry of blood, spleen and tumor

Peripheral blood and tumors were collected and analyzed by flow cytometry. Tumor tissue was dissociated into single cell suspensions as previously described.²⁶ Antibodies against human CD3 (BioLegend, Cat# 300308, RRID:AB_314044), CD4 (BioLegend, Cat# 357410, RRID:AB_2565662), CD8 (BioLegend, Cat# 300912, RRID:AB_314116), and CD45 (BioLegend, Cat# 304012, RRID:AB_314400) were used to quantify T cell engraftment and subpopulations. Fluorescence of stained cells was acquired using either a BD FACS-Calibur or a BD LSRFortessa (BD Biosciences, Heidelberg, Germany) and analyzed using FlowJo V.10.6.0 software (FlowJo, Ashland, Oregon).

Immunohistochemical staining

Fresh tumors were embedded in Tissue-Tek OCT (Miles Laboratories, Elkhart, Indiana) and snap-frozen in liquid nitrogen for storage at -80°C . The tumor sections were stained with mouse IgG3 mAb 3F8, as previously described.²⁷ Paraffin-embedded tumor sections were tested for T cell infiltration using immunohistochemical (IHC) staining of human CD3, CD4, and CD8 T cells performed by the Molecular Cytology Core Facility of MSKCC using Discovery XT processor (Ventana Medical Systems), as previously described.²⁶ Histological images were acquired with NIS-Elements V.4.0 imaging software and Nikon ECLIPSE Ni-U microscope.

Statistics

Statistical analysis of tumor growth or cytokine release was conducted using area under the curve (AUC). Two-tailed Student's t-test was used to determine statistical difference between two sets of data, while one-way analysis of variance with Tukey's post-hoc test was used to determine statistical differences among three or more sets of data. All statistical analyses were performed using GraphPad Prism V.8.0 for Windows (GraphPad Software, La Jolla, California; www.graphpad.com). $P < 0.05$ was considered statistically significant. Asterisks indicate that the experimental p value is statistically different from the associated controls at * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, and **** $p < 0.0001$.

RESULTS

T cells armed with GD2-BsAb built on the IgG-[L]-scFv platform had superior antitumor potency

We armed T cells with the major formats of GD2-BsAb (figure 1A) and compared the efficacy. The biochemical




Figure 1 Bispecific antibody platform has profound effects on the antitumor activity of bispecific antibody armed T cell immunotherapy. (A) BsAb structural platform. (B) BsAb armed T cells were stained with anti-idiotype antibody, and surface BsAb densities were measured as MFI by flow cytometry. (C) Antibody-dependent T cell-mediated cytotoxicity assay of GD2-BsAb armed T cells at increasing BsAb arming doses. The effector to target cell ratio (E:T ratio) was 10:1. (D) 2×10^7 of T cells were armed with 2 μ g of each BsAb and administered intravenously two doses per week for 2–3 weeks in GD2(+) osteosarcoma PDX and GD2(+) neuroblastoma PDX mouse models. In vivo antitumor responses were compared among groups. (E) Immunohistochemical staining of CD3(+) tumor infiltrating lymphocytes in neuroblastoma PDX tumors treated with a variety of GD2-BsAb armed T cells (on day 10 after the beginning of treatment). (F) Surface BsAb density (MFI) of HER2-BsAb armed T cells. (G) HER2-BsAb armed T cell induced cytotoxicity against osteosarcoma cell line U-2 OS at an E:T ratio of 10:1. (H) HER2-BsAb armed T cells (2 μ g of HER2-BsAb/ 2×10^7 of T cells) were administered intravenously twice per week for 3 weeks in HER2(+) osteosarcoma PDX-bearing mice. In vivo antitumor effect was compared. ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$. BiTE, Bi-specific T-cell engagers; BsAb, bispecific antibodies; GD2, disialoganglioside; HER2, human epidermal growth factor receptor 2; MFI, mean fluorescence intensity; PDX, patient-derived tumor xenograft; scFv, single-chain variable fragment.

properties of GD2-BsAbs are summarized in online supplemental table 3. Surface BsAb densities (measured by MFIs) on T cells were analyzed in [figure 1B](#). While chemical conjugate (IgG conjugate) armed T cells had lower MFIs, other GD2-BsAb armed T cells showed comparable MFIs. In vitro cytotoxicity assay showed that IgG-[L]-scFv or monomeric bi-specific T-cell engagers (BiTE) armed T cells had the strongest in vitro potency, while dimeric BiTE or IgG conjugate armed T cells had comparable cytotoxicity ([figure 1C](#)). To compare in vivo antitumor potency, a fixed dose of T cells armed with different GD2-BsAb formats (2 µg of each BsAb/2×10⁷ T cells) was intravenously administered into PDX-bearing mice ([figure 1D](#) and online supplemental figure 1). All EATs were well tolerated irrespective of BsAb formats, but only IgG-[L]-scFv GD2-BsAb armed T cells (GD2-EATs) exerted significant and durable antitumor responses prolonging survival. The in vivo efficacy of GD2-BsAb armed T cells strongly correlated with the density of tumor infiltrating CD3(+) T cells (TILs) by IHC staining of PDXs ([figure 1E](#)); GD2-EATs (T cells armed with GD2-IgG-[L]-scFv) showed substantially more abundant TILs compared with those armed with other BsAb formats.

Alongside GD2-BsAb armed T cells, we also compared the efficacy between HER2-EATs (armed with HER2-IgG-[L]-scFv) and HER2-IgG conjugate (Herceptin × OKT3) armed T cells proven safe in clinical trials.^{9,28} HER2-EATs showed higher BsAb densities (MFIs) ([figure 1F](#)) and more potent tumor cell killing than HER2-IgG conjugate armed T cells ([figure 1G](#)). HER2-EATs were much more effective in vivo for tumor response ($p < 0.01$) and for survival ($p = 0.0020$) ([figure 1H](#)).

EATs acquired target antigen-specific cytotoxicity

With this IgG-[L]-scFv BsAb platform we conducted the rest of our experiments. Given the finite CD3 TCR density on human T cell,²⁹ we set out to identify the optimal BsAb density on T cell. The in vitro cytotoxicity of EAT over a range of E:T ratios and BsAb arming dosages was studied ([figure 2A](#)). GD2-EATs and HER2-EATs both showed maximal cytotoxicity between 0.05 µg and 5 µg of BsAb/1×10⁶ T cells where quantitated between 500 and 20,000 BsAb molecules per T cell ([figure 2B](#)). When we compared the in vitro cytotoxicity of EATs with soluble BsAb under identical E:T ratios ([figure 2C](#)), the potencies of GD2-EATs and HER2-EATs were ~10-fold lower (EC_{50}) than soluble BsAbs; however, the maximal killing efficacy was comparable.

BsAb delivered on T cells had reduced cytokine release

Next, we compared cytokine release between EATs and T cells in the continuous presence of BsAb (BsAb plus T cells). Cytokine release was evaluated throughout each step of T cell arming ([figure 3A](#)). First, Th1 cell cytokines (IL-2, IL-6, IL-10, IFN-γ, and TNF-α) were measured in the supernatants after 20 min incubation (prewash) and then after the washing step (postwash) ([figure 3B](#)). Although the released cytokine levels were generally

low, IFN-γ and TNF-α did increase with the increment of GD2-BsAb (online supplemental figure 2A), which were removed after the washing steps (online supplemental figure 2B). Next, after co-culture with target cells, T cell cytokine levels were measured again and compared among groups. The cytokines surged after exposure to target cells. Both GD2-EATs and T cells coincubated with GD2-BsAb (GD2-BsAb plus T cells) released more cytokines in proportion to BsAb dose (online supplemental figure 2C,D). However, GD2-EATs produced significantly less amount of IL-2 ($p = 0.0071$), IL-10 ($p = 0.0203$), IFN-γ ($p = 0.0043$), and TNF-α ($p = 0.0162$) compared with GD2-BsAb plus T cells. Finally, we analyzed in vivo cytokine levels at different time points after GD2-EAT or GD2-BsAb plus T cell injection ([figure 3D](#) and online supplemental figure 3). GD2-EATs showed an early IL-2 and IFN-γ release, while GD2-BsAb plus T cells showed a surge of TNF-α at 4 hours and IL-6 at 48 hours. The AUC for TNF-α was significantly higher in GD2-BsAb plus T cells compared with GD2-EATs ($p = 0.0033$).

EATs facilitate T cell trafficking into tumors

T cell trafficking and persistence in tumors play an essential role in tumor immunity. To quantitate how efficiently EATs traffic into tumors and persist in vivo, we generated luciferase transduced T cells and armed with GD2-BsAb. Luc(+) GD2-EATs or Luc(+) unarmed T cells were intravenously administered into neuroblastoma PDX-bearing mice. Without GD2-BsAb arming, Luc(+) T cells did not localize to tumors and dissipated. In contrast, Luc(+) GD2-EATs rapidly trafficked into GD2(+) tumors following a transient sequestration in the lungs on day 1. The luciferase signals (total flux) of GD2-EATs in tumors increased over time to peak on day 4 ([figure 4A,C](#)). On the other hand, Luc(+) unarmed T cells with intravenous GD2-BsAb showed delayed egress from the lungs and the liver, and the bioluminescence signals in tumors peaked around day 7 ([figure 4B,C](#)). As tumors regressed, the total bioluminescence of Luc(+) GD2-EATs also diminished ([figure 4C,D](#)). In a second set of EAT trafficking study using osteosarcoma PDX model, EATs persisted longer with residual tumors ([figure 4E,F](#)). The bioluminescence of Luc(+) GD2-EATs or Luc(+) HER2-EATs in tumors peaked around day 5 and diminished slowly with still detectable signals over 1 month ([figure 4G](#)).

EATs showed potent antitumor activity with minimal toxicities in vivo

Autologous GD2-EATs were equally effective in vivo

To remove allogeneic T cell-induced graft-versus-xenograft effect in humanized mouse models,^{30,31} we tested autologous T cells derived from the same donor of tumor xenografts and evaluated the antitumor response of EATs (online supplemental figure 4). Autologous GD2-EATs significantly suppressed tumor growth, demonstrating the antitumor response of EATs is independent from the allogeneic ‘graft-versus-cancer’ effect, which has been a confounding factor for efficacy and toxicity




Figure 2 Ex vivo arming of T cells with IgG-[L]-scFv-platformed BsAb. (A) Antibody-dependent T cell-mediated cytotoxicity assay of GD2-EATs and HER2-EATs at increasing effector to target ratios (E:T ratios) and at increasing BsAb doses. (B) Surface BsAb density on EAT was analyzed using anti-human IgG Fc-specific antibody and anti-mouse quantum beads. Geometric MFIs of GD2-EATs and HER2-EATs were measured with increasing arming dose of either GD2-BsAb or HER2-BsAb, and BsAb density (MFI) on EAT was referenced to antibody binding capacity (ABC). (C) Comparison of in vitro cytotoxicity between EATs and soluble BsAb with identical E:T ratios, for both anti-GD2 and anti-HER2 systems. BsAb, bispecific antibodies; EATs, ex vivo armed T cells; GD2, disialoganglioside; HER2, human epidermal growth factor receptor 2; MFI, mean fluorescence intensities.

assessment in humanized mouse models. Since autologous T cell-PDX pairs were in short supply, we proceeded with the rest of EAT studies using random donor T cells.

EATs exerted significant antitumor effects in a variety of tumor targets

In vivo antitumor effects of EATs were tested in a panel of xenograft mouse models. Four to six doses of EATs (10 μg of each BsAb/2x10⁷ cells) were administered intravenously with a frequency of two doses per week. GD2-EATs were tested against neuroblastoma PDXs (Piro20Lung), neuroblastoma cell line (IMR32Luc) xenografts, and melanoma cell line (M14Luc) xenografts, respectively

(online supplemental figure 5). HER2-EATs were tested against osteosarcoma PDXs (TEOS1C), breast cancer PDXs (M37), and osteosarcoma cell line (143BLuc) xenografts (online supplemental figure 6). Beyond GD2 and HER2, EATs targeting other cancer antigens including STEAP1 (six transmembrane epithelial antigen prostate-1) on Ewing sarcoma cell line (TC71), PSMA (prostate membrane antigen) on prostate cancer cell line (LNCaP-AR), and EGFR (epidermal growth factor receptor) on osteosarcoma cell line (143B) were tested against each target cell line xenograft (online supplemental figure 7); in each instance, EATs exerted significant




Figure 3 Ex vivo arming of T cells could significantly reduce cytokine release. (A) Th1 cell cytokines (IL-2, IL-6, IL-10, IFN- γ , and TNF- α) released by T cells were measured in each step of arming: (a) in the supernatants after 20 min of incubation with GD2-BsAb (prewash), (b) after the second washing step (postwash), and (c and d) after incubation with target cells (GD2(+)) M14 melanoma cell line) at 37°C for 4 hours. (B) Cytokine release was compared between prewash supernatants (a) and postwash supernatants (b). (C) Cytokine release was compared between GD2-BsAb plus T cells (c), GD2-EATs (d) and unarmed T cells after exposure to target antigen. (D) After intravenous injection of GD2-EATs (armed with 10 μ g of GD2-BsAb/2 \times 10⁷ cells) or GD2-BsAb (10 μ g) plus unarmed T cells (2 \times 10⁷ cells) into osteosarcoma PDX-bearing mice, serum Th1 cytokine levels were measured at different time points. *P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001. BsAb, bispecific antibody; EATs, ex vivo armed T cells; GD2, disialoganglioside; IFN, interferon; IL, interleukin; PBS, phosphate-buffered saline; PDX, patient-derived tumor xenograft; Th1, T helper 1; TNF, tumor necrosis factor.




Figure 4 EATs showed faster tumor homing kinetics than BsAb-directed unarmed T cells, rapidly bypassing lung sequestration. Luciferase transduced T cells were expanded and armed with BsAb (Luc(+)) GD2-EATs. Luc(+) GD2-EATs ($10\mu\text{g}$ of GD2-BsAb/ 2×10^7 T cells) or Luc(+) unarmed T cells (2×10^7 cells) with or without GD2-BsAb ($10\mu\text{g}$) were administered intravenously into GD2(+) neuroblastoma PDX mice when the average tumor volume reached 100mm^3 . (A) Bioluminescence images of GD2-EATs trafficking into tumors over days. (B) Bioluminescence images of GD2-BsAb directed unarmed T cell trafficking into tumors over days. (C) Quantitation of T cell infiltration into tumors over time measured by bioluminescence (n=5 mice/group) expressed as total flux or radiance (photons/s) per pixel integrated over the tumor contour (ROI). (D) Tumor growth curves of individual mice treated with GD2-EATs, GD2-BsAb plus unarmed T cells, or unarmed T cells. To test the in vivo persistence of target antigen-specific EATs, Luc(+) GD2-EATs (armed with $10\mu\text{g}$ of GD2-BsAb/ 2×10^7 T cells) or Luc(+) HER2-EATs ($10\mu\text{g}$ of HER2-BsAb/ 2×10^7 T cells) were intravenously administered into osteosarcoma TEOS1C PDX-bearing mice. Additional two doses of non-luciferase transduced GD2-EATs or HER2-EATs were administered on day 7 and day 14. (E) Quantitation of bioluminescence of Luc(+) EATs in tumors post-treatment. (F) Tumor growth curves of individual mice treated with GD2-EATs, HER2-EATs, or unarmed T cells, or no treatment. (G) Bioluminescence images of Luc(+) GD2-EATs (upper) or Luc(+) HER2-EATs (lower) in tumors over time. Bioluminescence of Luc(+) EATs was detected over 28 days postinjection. BsAb, bispecific antibodies; EATs, ex vivo armed T cells; GD2, disialoganglioside; HER2, human epidermal growth factor receptor 2; PDX, patient-derived tumor xenograft; ROI, region of interest.

antitumor effects, without weight loss or adverse events during follow-up period (online supplemental figure 8).

Factors determining in vivo efficacy of EATs

BsAb dose for arming

In vitro tumor cell killing by EATs showed the best efficacy at arming doses between 0.05 μg and 5 μg of BsAb/ 1×10^6 T cells, corresponding to BsAb surface densities between 500 and 20,000 molecules per T cell. In vivo studies of EATs suggest minimum requirement of BsAb for arming ($>1 \mu\text{g}$ of BsAb/ 2×10^7 T cells (0.05 $\mu\text{g}/1 \times 10^6$ cells)) for consistent treatment outcome (figure 5A). When delivered by EATs, 1 μg of BsAb was substantially inferior to 10 μg or 100 μg of BsAb. In contrast to separate BsAb injection, where high-dose BsAb (100 μg of HER2-BsAb) showed inferior antitumor effect compared with low-dose BsAb ($p=0.0056$) (online supplemental figure 9A), 100 μg of HER2-BsAb was equally effective as 10 μg of HER2-BsAb when delivered by EATs ($p=0.2448$).

To investigate the BsAb dose and T cell response relationship, CD3(+) T cells were incubated with or without target cells at 37°C for 4 hours in the presence of increasing BsAb dose (5 $\times 10^{-5}$ μg to 50 μg of HER2-BsAb/ 1×10^6 T cells). T cells were analyzed for activation (CD69), exhaustion (TIM-3), activation induced T cell apoptosis and death (annexin V and 7-aminoactinomycin D, 7-AAD) and compared with HER2-EATs under identical conditions (online supplemental figure 9B). While CD69 and TIM-3 expression rose when HER2-BsAb was above 0.05 $\mu\text{g}/1 \times 10^6$ T cells, 7-AAD or annexin V expression started to increase above 0.5 $\mu\text{g}/1 \times 10^6$. All four markers were consistently and significantly lower for HER2-EATs when compared with HER2-BsAb plus T cells, in agreement with the in vivo antitumor effect of high-dose BsAb when delivered as soluble BsAb versus EATs.

Infused EAT cell number

Next, we evaluated the effect of infused EAT cell number on antitumor response in vivo (figure 5B). At a fixed arming dose of 0.5 μg of BsAb/ 1×10^6 cells, different cell numbers of GD2-EAT or HER2-EAT (5 $\times 10^6$ cells, 1×10^7 cells, and 2×10^7 cells) were administered twice weekly for 2 weeks. The antitumor effect consistently increased with the cell number of EATs infused. The in vivo antitumor effect of 2×10^7 of GD2-EATs was significantly superior to 5 $\times 10^6$ or 1×10^7 of GD2-EATs ($p=0.0018$ and $p=0.0366$, respectively). The effect of 2×10^7 of HER2-EATs was also superior to 5 $\times 10^6$ or 1×10^7 of HER2-EATs ($p=0.0077$ and $p=0.0340$, respectively). This antitumor response was correlated with the percentage of human CD45(+) TILs, which was obvious with 2×10^7 of GD2-EATs, but negligible with 5 $\times 10^6$ of GD2-EATs (online supplemental figure 10).

Treatment schedule

To evaluate the impact of treatment interval on the in vivo efficacy of EATs, we tested three different schedules: arm 1, low intensity (1 dose/week); arm 2, standard (2 doses/week); or arm 3, dose-dense (3 doses/week) (figure 5C).

GD2-EATs were fixed at 2 μg GD2-BsAb/ 2×10^7 cells. Dose-dense schedule contributed to improved tumor control over standard or low-intensity treatment schedules. Arm 3 showed the most potent antitumor effect against rapidly growing neuroblastoma PDXs compared with arm 2 (standard) or arm 1 (low-intensity schedules) ($p=0.0276$ and $p=0.0001$, respectively), which translated into survival benefit (both $p<0.0001$).

Supplemental EATs enabled long-term remission, prolonging survival

To test the effect of repeat EAT dosing on long-term remission and whether supplemental BsAb could eliminate the necessity of repeat EAT, we tested three different treatment schedules on osteosarcoma PDXs (figure 5D and online supplemental figure 11A): arm 1, two doses of EATs followed by six doses of intravenous BsAb; arm 2, four doses of EATs followed by four doses of BsAbs; and arm 3, eight doses of EATs. In contrast to the rapid tumor growth with no treatment or eight doses of unarmed T cells, two doses of GD2-EATs or HER2-EATs successfully ablated tumors. However, additional doses of EATs were beneficial in maintaining long-term remission. Contrary to the mice treated with two doses of GD2-EATs showing short-term response, those treated with eight doses of GD2-EATs, two of five mice showed sustained remission past 6 months, demonstrating statistically significant survival benefit over two doses or four doses of GD2-EATs supplemented with identical doses of GD2-BsAb ($p=0.0018$ and $p=0.0089$, respectively). Eight doses of HER2-EATs also showed a benefit in sustaining long-term remission over two doses or four doses of HER2-EATs supplemented with HER2-BsAb ($p=0.0018$ and $p=0.0494$, respectively) (online supplemental figure 11B). When we analyzed the relapsed tumors, those treated with GD2-EATs lost their GD2 expression (online supplemental figure 12), suggesting that tumor antigen downregulation or loss following treatment led to immune evasion.

Expanding the clinical utility of EAT therapy

EATs retain antitumor properties after cryopreservation

We tested EATs for their viability, BsAb surface density, and tumoricidal activities after a freeze-thaw process. After thawing at 37°C, EATs remained over 85% viable, irrespective of whether they were frozen for 2 hours at -80°C or up to 12 months in liquid nitrogen. When the thawed EATs were stained with anti-idiotypic antibody or anti-human IgG Fc antibody, BsAb surface density remained comparable with freshly armed EATs (fresh EATs) by MFIs (figure 6A). The CD4:CD8 ratio was preserved after freeze-thaw (online supplemental figure 13A). However, the thawed CD4(+) GD2-EATs expressed more apoptosis marker than CD8(+) GD2-EATs compared with freshly armed GD2-EATs. Although the maximal killing of target cells did diminish after freeze-thaw (50% of maximal killing efficacy of fresh EATs) due to not enough recovery time after thawing, antigen specificity and the potency of EAT were maintained (figure 6B).




Figure 5 Factors determining the in vivo efficacy of EATs. (A) The effect of BsAb dose on in vivo efficacy of EATs. 2x10⁷ of T cells were armed with increasing dose of GD2-BsAb or HER2-BsAb and their antitumor effects were compared. (B) The effect of EAT cell number on the in vivo efficacy of EATs. At a fixed arming dose of 0.5 µg of BsAb/1x10⁶ cells, increasing numbers of GD2-EAT or HER2-EAT (5x10⁶ cells, 1x10⁷ cells, and 2x10⁷ cells) were administered. (C) The effect of EAT treatment schedule on the in vivo efficacy of EATs. GD2-EATs (2 µg of GD2-BsAb/2x10⁷ cells) were administered as low intensity (1 dose/week in arm 1), standard (2 doses/week in arm 2), or dose-dense (3 doses/week in arm 3) and their in vivo antitumor response and survival were compared. (D) The effect of total number of doses of EATs on long-term tumor control and survival. Arm 1, GD2-EATs (10 µg of GD2-BsAb/2x10⁷ cells) were administered twice weekly for 1 week, and GD2-BsAb (10 µg/dose) were followed twice weekly for 3 weeks; arm 2, four doses of GD2-EATs followed by four doses of GD2-BsAb; arm 3, eight doses of GD2-EATs. *P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001. BsAb, bispecific antibody; EATs, ex vivo armed T cells; GD2, disialoganglioside; HER2, human epidermal growth factor receptor 2; PDX, patient-derived tumor xenograft; sc, subcutaneous.




Figure 6 Cryopreserved EATs retained target antigen-specific cytotoxicity and exerted a comparable antitumor activity. (A) Geometric mean fluorescence intensities of BsAb on GD2-EATs ($0.5 \mu\text{g}$ of GD2-BsAb/ 10^6 cells) and HER2-EATs ($0.5 \mu\text{g}$ of HER2-BsAb/ 10^6 cells) before and after cryopreservation. (B) Antibody-dependent T cell-mediated cytotoxicity assay of GD2-EATs and HER2-EATs against GD2(+) and HER2(+) osteosarcoma cell lines before and after cryopreservation ($n=6$). (C) In vivo antitumor response of thawed GD2-EATs. T cells were first armed with GD2-BsAb ($10 \mu\text{g}$ of BsAb/ 2×10^7 cells) before cryopreservation. These cells were then thawed and administered into mice bearing GD2(+) osteosarcoma PDX to compare their in vivo antitumor potency with freshly armed GD2-EATs derived from the same donor. Four to six doses of cryopreserved (thawed) GD2-EATs or freshly armed (fresh) GD2-EATs were administered intravenously twice per week. (D) Relative body weights over time after treatment with fresh or thawed GD2-EATs. (E) Flow cytometry analyses of peripheral blood (PB) T cells in the mice treated with fresh or thawed GD2-EATs on day 35 after treatment. (F) In vivo antitumor response of thawed GD2-EATs or HER2-EATs against telangiectatic osteosarcoma PDXs. T cells were first armed with GD2-BsAb or HER2-BsAb ($10 \mu\text{g}$ of BsAb/ 2×10^7 cells) before cryopreservation. Six doses of GD2-EATs or HER2-EATs were given twice a week for 3 weeks with SC interleukin-2. Both thawed EATs significantly suppressed tumor growth without weight loss, improving survival ($p < 0.0001$). $***P < 0.001$, $****P < 0.0001$. ATC, activated T cells; EATs, ex vivo armed T cells; E:T, effector to target cell ratio; GD2, disialoganglioside; HER2, human epidermal growth factor receptor 2; PDX, patient-derived tumor xenograft.

In vivo antitumor activities of thawed EATs were evaluated in two different osteosarcoma PDX models. Thawed GD2-EATs exerted potent and comparable antitumor effect to fresh GD2-EATs ($p=0.1633$) and significantly prolonged survival compared with controls ($p=0.0002$) (figure 6C). Four of five mice treated with thawed GD2-EATs showed long-term remission past 6 months post-treatment. IHC staining of the tumors treated with thawed GD2-EATs showed diffuse infiltration of CD4(+) T cells as well as CD8(+) T cells (online supplemental figure 13B), supporting their intact homing properties. Interestingly, while the mice treated with fresh GD2-EATs developed mild to moderate GVHD 1–2 months post-treatment, the mice treated with thawed GD2-EATs did not present clinical signs of GVHD throughout the entire follow-up period, maintaining body weight, good coat condition and general activity (figure 6D). When blood samples were analyzed on day 45 post-treatment (figure 6E), the fresh GD2-EATs-treated mice showed CD4(+) T cell predominance with signs of xenogeneic GVHD, but the thawed GD2-EATs-treated mice displayed a predominance of CD8(+) T cells without signs of GVHD, correlating with their clinical manifestations. The comparable in vivo potency of thawed EATs was confirmed in the second tumor model (figure 6F); both thawed GD2-EATs and thawed HER2-EATs exerted significant antitumor effect against osteosarcoma PDXs ($p<0.0001$) and improved survival ($p<0.0001$) compared with controls. All tumors regressed without toxicities, and there were no signs of GVHD or tumor relapse past 4 months post-treatment.

$\gamma\delta$ T cells are equally effective as $\alpha\beta$ T cells

Since CD3 is present on diverse subpopulations of T cells, all kinds of effector T cells should be able to arm T-BsAb. We tested the potential applicability of EATs using $\gamma\delta$ T cells known to have a reduced alloreactivity with potential as an allogeneic ‘off-the-shelf’ T cell source.³² After expansion from fresh PBMCs with IL-2 and zoledronate for 12 days, most of CD3(+) T cells were $\gamma\delta$ TCR(+) (online supplemental figure 14A). Majority of the $\gamma\delta$ T cells were CD3 positive and CD4 and CD8 double negative, contrasting with T cells expanded using CD3/CD28 beads, where majority were $\alpha\beta$ TCR positive and CD4 or CD8 positive (online supplemental figure 14B). After arming $\gamma\delta$ T cells with GD2-BsAb ($\gamma\delta$ -GD2-EATs) or HER2-BsAb ($\gamma\delta$ -HER2-EATs), surface BsAb density was measured by flow cytometry, and their MFIs were comparable with those of $\alpha\beta$ -EATs (figure 7A). In the presence of GD2-BsAb or HER2-BsAb, $\gamma\delta$ T cells mediated potent tumoricidal activity in vitro, exceeding the efficacy of $\alpha\beta$ -EATs (figure 7B). The maximal cytotoxicity of $\gamma\delta$ -GD2-EATs and $\gamma\delta$ -HER2-EATs was achieved at arming doses between 0.05 μg and 5 μg of BsAb/ 1×10^6 T cells (figure 7C), where antigen-specific cytotoxicity was maintained after freeze and thaw (figure 7D).

We next tested the in vivo efficacy of $\gamma\delta$ -EATs and compared with corresponding $\alpha\beta$ -EATs (online supplemental figure 15A). With supplementary IL-2,

$\gamma\delta$ -GD2-EATs and $\gamma\delta$ -HER2-EATs did not produce significant antitumor response irrespective of additional zoledronate. Flow cytometry analyses of T cells in the blood and tumors after $\gamma\delta$ -EAT treatment presented substantially fewer human CD45(+) T cells in the circulation and in the tumors compared with $\alpha\beta$ -EATs ($p=0.0006$ and $p=0.0007$, respectively), suggesting poor in vivo survival of $\gamma\delta$ -EATs (online supplemental figure 15B).

However, when exogenous IL-15 (as IL15R α -IL15 complex) instead of IL-2 was used as T cell survival cytokine, the in vivo frequencies of $\gamma\delta$ -EATs significantly increased (figure 7E). $\gamma\delta$ T cells expanded from fresh PBMCs using 2 μM of zoledronate plus 30 ng/mL of IL-15 for 12–14 days were armed with GD2-BsAb or HER2-BsAb and administered intravenously into osteosarcoma PDX-bearing mice, with 5 μg of subcutaneous IL-15 or 1000 IU of IL-2 (figure 7F and online supplemental figure 16A). While $\gamma\delta$ -GD2-EATs and $\gamma\delta$ -HER2-EATs sustained with IL-2 failed to suppress tumor, same $\gamma\delta$ -EATs sustained with IL-15 exerted significant antitumor effects without toxicities or weight loss during follow-up period. The PDXs treated with $\gamma\delta$ -GD2-EATs plus IL-15 showed a diffuse T cell infiltration into tumors, in contrast to tumors treated by $\gamma\delta$ -GD2-EATs plus IL-2 or unarmed $\gamma\delta$ -EATs plus IL-15 (online supplemental figure 16B). Furthermore, cryopreserved $\gamma\delta$ -EATs showed strong in vivo antitumor effect when supplemented with IL-15 and zoledronate (online supplemental figure 17A). Thawed $\gamma\delta$ -STEAP1-EATs exerted a significant antitumor response against STEAP1(+) Ewing sarcoma PDXs in vivo. These findings implicate the potential applicability of IL-15 and allogeneic $\gamma\delta$ T cells for IgG-[L]-scFv-platformed BsAb arming for the treatment of human cancers.

DISCUSSION

For successful BsAb-directed T cell immunotherapy, adequate number and quality of tumor-directed T cells are required. Unfortunately, autologous T cells of patients with cancer are often dysfunctional, exhausted, or compromised by chemotherapy or the cancer itself.³³ Here we show that ex vivo expanded T cells armed with BsAb of IgG-[L]-scFv platform can be transformed into living drugs producing robust antitumor response. EATs produced significantly less TNF- α compared with direct BsAb injection, while infiltrating tumors faster to produce robust tumoricidal activity. EATs mediate significant antitumor effect in an autologous system, excluding the allogeneic T cell effect in the humanized mouse models. The feasibility of cryopreservation should allow ample time for detailed quality control of EATs before release, facilitating product storage and distribution. By harvesting autologous T cells before intensive chemotherapy or using healthy third-party or haploidentical donor’s alternative effector T cells with reduced alloreactivity, the clinical potential of this approach can be further expanded.

For BsAb armed T cell immunotherapy, the BsAb structural format was critical in order to drive T cells to




Figure 7 EAT as a versatile platform to harness $\gamma\delta$ T cells. (A) Flow cytometry of GD2-BsAb or HER2-BsAb on $\gamma\delta$ T cells ($\gamma\delta$ Ts) or unselected polyclonal T cells (mostly $\alpha\beta$ T cells ($\alpha\beta$ Ts)) after arming with GD2-BsAb or HER2-BsAb. (B) ADTC assays of $\gamma\delta$ -GD2-EATs and $\gamma\delta$ -HER2-EATs compared with $\alpha\beta$ -GD2-EATs and $\alpha\beta$ -HER2-EATs. Non-specific tumor cell killing by unarmed $\gamma\delta$ T cells and unarmed $\alpha\beta$ T cells (background) were subtracted. (C) ADTC assay of $\gamma\delta$ -GD2-EATs and $\gamma\delta$ -HER2-EATs at increasing effector to target ratios (E:T ratios) and at increasing BsAb arming doses. (D) In vitro cytotoxicity against breast cancer cell line HCC1954 was compared between fresh $\gamma\delta$ -HER2-EATs and thawed $\gamma\delta$ -HER2-EATs at increasing E:T ratios and at increasing BsAb arming doses. (E) Flow cytometry analyses of peripheral blood T cells after second dose of $\gamma\delta$ -GD2-EATs plus zoledronate and supplementary IL-2 or IL-15. (F) Three doses of $\gamma\delta$ -GD2-EATs (10 μ g of GD2-BsAb/2x10⁷ cells) were administered with supplementary IL-2 or IL-15 to treat osteosarcoma PDXs and the antitumor response was compared among groups. *P<0.05, ***P<0.001. ADTC, antibody-dependent T cell-mediated cytotoxicity; BsAb, bispecific antibodies; EATs, ex vivo armed T cells; $\gamma\delta$ T cells, gamma delta T cells; IL, interleukin; MFI, mean fluorescence intensity; PDX, patient-derived tumor xenograft.

infiltrate 'cold' tumors to exert their antitumor effect. Despite similar antitumor properties among BsAb armed T cells *in vitro*, only 'EATs', T cells armed with the IgG-[L]-scFv-platformed BsAb, showed strong infiltration into tumors to produce durable antitumor responses which translated into prolonged survival. Although genetically engineered T cells expressing CD19-BiTE or CAR T cells secreting EGFR-BiTE had shown success in preclinical models,^{34 35} T cells *ex vivo* armed with GD2-BiTE have never been as successful. This may attribute to the short half-life of BiTE or the nature of the tumor target, partly explaining why there have been no successful reports of armed T cells using BiTE despite the clinical success of Blincyto.³⁶ Besides, protein size, distance of the epitope to the membrane, purity, and binding affinities to tumor and to CD3 T cells strongly affect the biodistribution and *in vivo* antitumor activities of T-BsAb.^{37–41} Since all GD2-BsAb platforms were built using the same anti-GD2 and anti-CD3 VH and variable light chain (VL) sequences, monovalent binding to CD3 or to target in monomeric BiTE and IgG heterodimer (online supplemental table 3) might affect the stability of BsAb armed T cells *in vivo*. However, despite the multivalency in dimeric BiTE, BiTE-Fc, IgG-[H]-scFv, and IgG conjugate, none of these platforms was able to achieve the potency of IgG-[L]-scFv, implicating additional factors besides binding avidity. We previously described the critical importance of inter-domain distance and cis-configuration of BsAb,¹⁴ now confirmed with these extensive series of EAT-based experiments. The mechanism behind the *in vivo* superiority of the IgG-[L]-scFv format is likely to be more complex.

One of the major toxicities of T cell-based immunotherapy is CRS,⁴² typically associated with surge of IFN- γ , IL-6, and TNF- α , although elevations of IL-2, granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-10, IL-8, and IL-5 have also been reported.^{43 44} IL-6 and TNF- α have been implicated as the central mediators of CRS.⁴² When the anti-CD28 antibody TGN1412 was administered to healthy subjects, CRS developed in an hour, coinciding with peak cytokine levels: TNF- α , as an initial trigger, was followed by INF- γ and IL-10, IL-8, IL-6, IL-4, IL-2, and IL-1 β .⁴⁵ When BsAb engages polyclonal T cells to undergo synchronous activation, TNF- α acts as the initial signal for monocyte activation, resulting in release of IL-6 and IL-1, preventable by anti-TNF- α antibodies without compromising antitumor activity.⁴⁶ However, the absence of cytokine storm in clinical studies of BsAb armed T cell is notable.^{12 13 47} T cells exposed to BsAb produced TNF- α during the initial 20 min of BsAb arming; after washing, EATs released significantly less cytokines, particularly TNF- α , *in vitro* and *in vivo* without affecting their trafficking ability or tumoricidal activity.

We also showed that thawed EATs maintained the viability and their affinity to target antigens and to CD3(+) T cells. The cryopreservation did not affect the frequency of CD4 or CD8 T cells in EATs. The thawed GD2-EATs preserved their target antigen specificity and were effective *in vitro* and *in vivo*. When thawed, the cryopreserved

CD4(+) GD2-EATs did have higher levels of apoptosis marker than CD8(+) GD2-EATs, which was consistent with the *in vivo* dominance of CD8(+) T cell population following treatment. CD4(+) T cell dysfunction including reduced IFN- γ production has been reported in the cryopreserved product of T cells, PBMCs or cord blood.^{48–50} To improve antitumor activity and to reduce treatment-related toxicity, optimizing cryopreservation protocols for EATs would be the next front.

Another limitation of CAR T cell therapy is the need for autologous T cells. Alternative effector T cells with low alloreactivity including human leukocyte antigen (HLA)-identical donor's activated T cells,^{51 52} clonally committed Epstein-Barr virus (EBV)-specific cytotoxic T cells,⁵³ and innate-like lymphocytes such as $\gamma\delta$ T cells or natural killer T (NKT) cells could be potential 'off-the-shelf' cytotherapy products. When obtained from healthy donors, the probability of successful large-scale *ex vivo* expansion of effector cells with consistent product quality should be high. $\gamma\delta$ T cells are known to have innate antitumor properties and significantly reduced alloreactivity or 'on-target off-tumor' toxicities.³² In our studies, $\gamma\delta$ -EATs could suppress osteosarcoma xenografts in the presence of the IL15R α -IL15 cytokine complex without toxicities. IL-15 enhanced proliferation of T cells *in vivo* and improved potency of T cell-based immunotherapy.^{54 55} For $\gamma\delta$ T cell treatment, poor *in vivo* survival has been a major challenge. Supplementary zoledronate and IL-15/IL-15Ra enabled $\gamma\delta$ -EATs to survive and to proliferate *in vivo* to exert significant antitumor effects. By employing optimal cytokines to prolong *in vivo* survival,⁵⁶ $\gamma\delta$ -EATs deserve to be explored in more depth. EATs using $\gamma\delta$ T cells should provide a powerful platform to harness third-party or haploidentical donor's effector T cells with minimal graft-versus-host side effects, with the additional benefit of cytotoxic mechanisms through TNF-related apoptosis-inducing ligand (TRAIL), NKG2D receptor, and Fc γ RIII (CD16).^{57 58}

Neurotoxicity is the other major hurdle that has plagued CAR T cell and BsAb.⁴ Since GD2 is expressed in mouse brain, several studies have reported neurotoxicity in mice when CAR T cells were used.⁵⁹ Although we did not directly compare EATs and CAR T cells in this manuscript, we previously compared the efficacy of GD2-CAR T cells and GD2 IgG-[L]-scFv BsAb built with identical anti-GD2 IgG sequence.⁶⁰ GD2-BsAb-driven T cells were more efficient than GD2-CAR T cells *in vivo*. More importantly, while GD2-CAR T cells caused neurological damage, neither GD2-BsAb nor GD2-EATs caused any neurotoxicity in mouse models.⁶¹

In conclusion, *ex vivo* arming of T cells with IgG-[L]-scFv BsAb is a potential strategy beyond CAR T cell technology to use proteins instead of genes to modify T cells. While avoiding CRS and neurotoxicity, the potential to use cryopreserved alternative effector T cells other than $\alpha\beta$ T cells should expand the clinical utility of EATs.

Acknowledgements We would like to especially thank Alan W Long, Tsung-Yi Lin, See Liang Ng, and Steven Tsung-Yi Lin for their valuable comments on earlier drafts. Steven Tsung-Yi Lin also designed and validated BsAbs to STEAP1 and PSMA. Hong-fen Guo tested the purity and stability of the BsAbs using HPLC and SDS-PAGE and analyzed endotoxin released by BsAb. Yi Feng stained fresh frozen tumor tissues with hu3F8 antibody. Dr Andrew Kung, Dr Filemon DeLa Cruz, and Dr Sarat Chandrapaty and Dr Elisa De Stanchina provided PDXs for these studies. Archana Thakur provided the Herceptin and hu3F8 chemical conjugates. Technical service was provided by the MSK Animal Imaging Core Facility, Antitumor Assessment Core Facility, and Molecular Cytology Core Facility.

Contributors JAP and N-KVC designed the experiments, interpreted and analyzed the results, and wrote the manuscript. LL provided hu3F8 IgG chemical conjugates and Herceptin IgG chemical conjugates. BS designed and validated the diverse formats of anti-GD2-BsAb. HX designed and validated the anti-HER2 BsAb and tested each BsAb's affinity to CD3 and to each target antigen.

Funding This work was supported by funds to N-KVC from R01 CA 182526, Enid A Haupt Endowed Chair, the Robert Steel Foundation, Kids Walk for Kids with Cancer, as well as sponsored research fund from Y-mAbs Therapeutics. Technical service provided by the MSK Animal Imaging Core Facility, Antitumor Assessment Core Facility, and Molecular Cytology Core Facility was supported in part by the NCI Cancer Center Support Grant P30 CA008748. LL was supported in part by the Marion McNulty Weaver and Malvin C Weaver Professor of Oncology Endowed Chair, R01 CA 182526, and NCI Cancer Center Support Grant P30 CA044579 at UVA.

Competing interests Both MSK and N-KVC have financial interest in Y-mAbs, Abpro-Labs and Eureka Therapeutics. N-KVC reports receiving commercial research grants from Y-mAbs Therapeutics and Abpro-Labs. N-KVC was named as inventor on multiple patents filed by MSK, including those licensed to Y-mAbs Therapeutics, Biotec Pharmacon, and Abpro-Labs. N-KVC is a SAB member for Abpro-Labs and Eureka Therapeutics. LL is cofounder of Transtarget and is a SAB member for Rapa Therapeutics. JAP has no disclosures to report.

Patient consent for publication Not required.

Ethics approval All animal experiments were approved by the Memorial Sloan Kettering's Institutional Animal Care and Use Committee (IACUC) and were executed according to the ACUC guidelines. Patient-derived tumor xenografts were established with MSKCC IRB approval.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Jeong A Park <http://orcid.org/0000-0003-3690-6747>

Nai-Kong V Cheung <http://orcid.org/0000-0001-6323-5171>

REFERENCES

- Park JH, Riviere I, Gonen M, *et al*. Long-Term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. *N Engl J Med* 2018;378:449–59.
- Topalian SL, Hodi FS, Brahmer JR, *et al*. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med* 2012;366:2443–54.
- Topp MS, Gökbuegü N, Zugmaier G, *et al*. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. *J Clin Oncol* 2014;32:4134–40.
- Velasquez MP, Bonifant CL, Gottschalk S. Redirecting T cells to hematological malignancies with bispecific antibodies. *Blood* 2018;131:30–8.
- Beatty GL, O'Hara M. Chimeric antigen receptor-modified T cells for the treatment of solid tumors: defining the challenges and next steps. *Pharmacol Ther* 2016;166:30–9.
- Gajewski TF. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. *Clin Cancer Res* 2007;13:5256–61.
- Moon EK, Wang L-C, Dolfi DV, *et al*. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. *Clin Cancer Res* 2014;20:4262–73.
- Gust J, Hay KA, Hanafi L-A, *et al*. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. *Cancer Discov* 2017;7:1404–19.
- Lum LG, Thakur A, Al-Kadhimi Z, *et al*. Targeted T-cell therapy in stage IV breast cancer: a phase I clinical trial. *Clin Cancer Res* 2015;21:2305–14.
- Yankelevich M, Kondadasula SV, Thakur A, *et al*. Anti-CD3 × anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets. *Pediatr Blood Cancer* 2012;59:1198–205.
- Reusch U, Sundaram M, Davol PA, *et al*. Anti-CD3 X anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model. *Clin Cancer Res* 2006;12:183–90.
- Vaishampayan U, Thakur A, Rathore R, *et al*. Phase I study of anti-CD3 X anti-HER2 bispecific antibody in metastatic castrate resistant prostate cancer patients. *Prostate Cancer* 2015;2015:1–10.
- Lum LG, Thakur A, Pray C, *et al*. Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma: a pilot study. *Bone Marrow Transplant* 2014;49:73–9.
- Santich BH, Park JA, Tran H, *et al*. Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies. *Sci Transl Med* 2020;12. doi:10.1126/scitranslmed.aax1315. [Epub ahead of print: 11 03 2020].
- Galon J, Angell HK, Bedognetti D, *et al*. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. *Immunity* 2013;39:11–26.
- Thakur A, Huang M, Lum LG. Bispecific antibody based therapeutics: strengths and challenges. *Blood Rev* 2018;32:339–47.
- Xu H, Buhtoiarov IN, Guo H, *et al*. A novel multimeric IL15/IL15R α -Fc complex to enhance cancer immunotherapy. *Oncoimmunology* 2021;10:1893500.
- Xu H, Cheng M, Guo H, *et al*. Retargeting T cells to GD2 pentasaccharide on human tumors using bispecific humanized antibody. *Cancer Immunol Res* 2015;3:266–77.
- Lopez-Albaitero A, Xu H, Guo H, *et al*. Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody. *Oncoimmunology* 2017;6:e1267891.
- Sen M, Wankowski DM, Garlie NK, *et al*. Use of anti-CD3 X anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors. *J Hematother Stem Cell Res* 2001;10:247–60.
- Hoseini SS, Guo H, Wu Z, *et al*. A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia. *Blood Adv* 2018;2:1250–8.
- Wu Z, Guo H-F, Xu H, *et al*. Development of a tetravalent Anti-GPA33/Anti-CD3 bispecific antibody for colorectal cancers. *Mol Cancer Ther* 2018;17:2164–75.
- Lopez-Albaitero A, Xu H, Guo H, *et al*. Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody. *Oncoimmunology* 2017;6:e1267891.
- Andrade D, Redecha PB, Vukelic M, *et al*. Engraftment of peripheral blood mononuclear cells from systemic lupus erythematosus and antiphospholipid syndrome patient donors into BALB-RAG-2-/- IL-2R γ -/- mice: a promising model for studying human disease. *Arthritis Rheum* 2011;63:2764–73.
- Ishiguro T, Sano Y, Komatsu S-I, *et al*. An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors. *Sci Transl Med* 2017;9. doi:10.1126/scitranslmed.aal4291. [Epub ahead of print: 04 Oct 2017].
- Park JA, Cheung N-KV. Gd2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma. *J Hematol Oncol* 2020;13:172.
- Dobrenkov K, Ostrovskaya I, Gu J, *et al*. Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults. *Pediatr Blood Cancer* 2016;63:1780–5.



- 28 Yankelevich M, Modak S, Chu R, *et al.* Phase I study of OKT3 X hu3F8 bispecific antibody (GD2Bi) armed T cells (GD2BATs) in GD2-positive tumors. *Journal of Clinical Oncology* 2019;37:2533.
- 29 Stone JD, Artyomov MN, Chervin AS, *et al.* Interaction of streptavidin-based peptide-MHC oligomers (tetramers) with cell-surface TCRs. *J Immunol* 2011;187:6281–90.
- 30 Ehx G, Somja J, Warnatz H-J, *et al.* Xenogeneic graft-versus-host disease in humanized NSG and NSG-HLA-A2/HHd mice. *Front Immunol* 2018;9:9.
- 31 Morton JJ, Bird G, Refaeli Y, *et al.* Humanized mouse xenograft models: narrowing the Tumor-Microenvironment gap. *Cancer Res* 2016;76:6153–8.
- 32 Fisher J, Anderson J. Engineering approaches in human gamma delta T cells for cancer immunotherapy. *Front Immunol* 2018;9:1409.
- 33 Ménétrier-Caux C, Ray-Coquard I, Blay J-Y, *et al.* Lymphopenia in cancer patients and its effects on response to immunotherapy: an opportunity for combination with cytokines? *J Immunother Cancer* 2019;7:85.
- 34 Velasquez MP, Torres D, Iwahori K, *et al.* T cells expressing CD19-specific Engager molecules for the immunotherapy of CD19-positive malignancies. *Sci Rep* 2016;6:27130.
- 35 Choi BD, Yu X, Castano AP, *et al.* Car-T cells secreting bites circumvent antigen escape without detectable toxicity. *Nat Biotechnol* 2019;37:1049–58.
- 36 Klinger M, Brandl C, Zugmaier G, *et al.* Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific bite antibody blinatumomab. *Blood* 2012;119:6226–33.
- 37 Stafflin K, Zuch de Zafra CL, Schutt LK, *et al.* Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody. *JCI Insight* 2020;5. doi:10.1172/jci.insight.133757. [Epub ahead of print: 09 Apr 2020].
- 38 Bluemel C, Hausmann S, Fluhr P, *et al.* Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by bite antibodies specific for a large melanoma surface antigen. *Cancer Immunol Immunother* 2010;59:1197–209.
- 39 Cuesta Ángel M., Sainz-Pastor N, Bonet J, *et al.* Multivalent antibodies: when design surpasses evolution. *Trends Biotechnol* 2010;28:355–62.
- 40 Ellerman D. Bispecific T-cell engagers: towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety. *Methods* 2019;154:102–17.
- 41 Mandikian D, Takahashi N, Lo AA, *et al.* Relative target affinities of T-cell-dependent bispecific antibodies determine biodistribution in a solid tumor mouse model. *Mol Cancer Ther* 2018;17:776–85.
- 42 Lee DW, Gardner R, Porter DL, *et al.* Current concepts in the diagnosis and management of cytokine release syndrome. *Blood* 2014;124:188–95.
- 43 Grupp SA, Kalos M, Barrett D, *et al.* Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. *N Engl J Med* 2013;368:1509–18.
- 44 Kochenderfer JN, Dudley ME, Feldman SA, *et al.* B-Cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. *Blood* 2012;119:2709–20.
- 45 Suntharalingam G, Perry MR, Ward S, *et al.* Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. *N Engl J Med* 2006;355:1018–28.
- 46 Li J, Piskol R, Ybarra R, *et al.* Cd3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity. *Sci Transl Med* 2019;11. doi:10.1126/scitranslmed.aax8861. [Epub ahead of print: 04 Sep 2019].
- 47 Lum LG, Thakur A, Choi M, *et al.* Clinical and immune responses to anti-CD3 X anti-EGFR bispecific antibody armed activated T cells (EGFR bats) in pancreatic cancer patients. *Oncoimmunology* 2020;9:1773201.
- 48 Owen RE, Sinclair E, Emu B, *et al.* Loss of T cell responses following long-term cryopreservation. *J Immunol Methods* 2007;326:93–115.
- 49 Weiner J, Duran-Struuck R, Zitsman J, *et al.* Restimulation after cryopreservation and thawing preserves the phenotype and function of expanded baboon regulatory T cells. *Transplant Direct* 2015;1:1–7.
- 50 Ford T, Wenden C, Mbekeani A, *et al.* Cryopreservation-related loss of antigen-specific IFN γ producing CD4. *Vaccine* 2017;35:1898–906.
- 51 Brudno JN, Somerville RPT, Shi V, *et al.* Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. *J Clin Oncol* 2016;34:1112–21.
- 52 Lum LG, Ramesh M, Thakur A, *et al.* Targeting cytomegalovirus-infected cells using T cells armed with anti-CD3 \times anti-CMV bispecific antibody. *Biol Blood Marrow Transplant* 2012;18:1012–22.
- 53 Dutour A, Marin V, Pizzitola I, *et al.* In vitro and in vivo antitumor effect of Anti-CD33 chimeric receptor-expressing EBV-CTL against CD33 acute myeloid leukemia. *Adv Hematol* 2012;2012:683065.
- 54 Pilipow K, Roberto A, Roederer M, *et al.* IL15 and T-cell stemness in T-cell-based cancer immunotherapy. *Cancer Res* 2015;75:5187–93.
- 55 Hurton LV, Singh H, Najjar AM, *et al.* Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. *Proc Natl Acad Sci U S A* 2016;113:E7788–97.
- 56 Van Acker HH, Anguille S, Willemsen Y, *et al.* Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells. *J Hematol Oncol* 2016;9:101.
- 57 Zhao Y, Niu C, Cui J. Gamma-delta ($\gamma\delta$) T cells: friend or foe in cancer development? *J Transl Med* 2018;16:3.
- 58 Liu Y, Zhang C. The role of human $\gamma\delta$ T cells in anti-tumor immunity and their potential for cancer immunotherapy. *Cells* 2020;9:1206.
- 59 Richman SA, Nunez-Cruz S, Moghimi B, *et al.* High-Affinity GD2-Specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model. *Cancer Immunol Res* 2018;6:36–46.
- 60 Hoseini SS, Dobrenkov K, Pankov D, *et al.* Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2. *Oncoimmunology* 2017;6:e1320625.
- 61 Santich B, Hoseini S, Suzuki M. 41BB or CD28 driven disialoganglioside (GD2)-specific CAR-T, but not T-cell engaging bispecific antibody, induces fatal neurotoxicity in mice. In: *Advances in Neuroblastoma Research 2021 Annual Meeting; Virtual 2021* <https://www.anr2021.org/resources/uploads/sites/26/2021/01/Abstract-book-Oral-presentations-1.pdf>
- 62 Grabert RC, Cousens LP, Smith JA, *et al.* Human T cells armed with HER2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation. *Clin Cancer Res* 2006;12:569–76.

Supplementary Materials for

Potent Ex Vivo Armed T Cells Using Recombinant Bispecific Antibodies for Adoptive
Immunotherapy with Reduced Cytokine Release

Running title: Ex Vivo Armed T cells with Bispecific Antibodies for Adoptive Immunotherapy

Jeong A Park, M.D., Ph. D.¹Brian Santich, Ph.D.¹Hong Xu, Ph.D.¹Lawrence G. Lum, M.D., D.Sc.²Nai-Kong V. Cheung, M.D., Ph.D.^{1*}***Corresponding author:**

Nai-Kong V. Cheung

Department of Pediatrics

Memorial Sloan Kettering Cancer Center

1275 York Ave, Box 170

New York, NY 10065.

Phone: +1 646-888-2313

Email: cheungn@mskcc.org

Supplementary table 1. Purity, affinity and endotoxin content of bispecific antibody preparations.

Antigen	Antibody	Antibody format	Purity (%)	Binding affinity K_d (M)		Endotoxin (EU/mg)
			HPLC	CD3	Target antigen	
GD2	hu3F8	IgG-[L]-scFv	96.23	2.86E-09	3.61E-09	<2
HER2	trastuzumab	IgG-[L]-scFv	93.36	2.30E-09	1.34E-12	<2
CD33	huM195	IgG-[L]-scFv	82.54	2.01E-08	2.47E-09	<2
GPA33	huA33	IgG-[L]-scFv	91.06	3.56E-09	3.05E-10	<2
STEAP1	hu1SX2	IgG-[L]-scFv	94.741	4.16E-09	ND	<2
PSMA	huJ591	IgG-[L]-scFv	87.243	5.70E-09	1.03E-09	<2
EGFR	cetuximab	IgG-[L]-scFv	92.753	1.52E-08	2.66E-10	<2

ND = Not done because the binding epitope was lost from soluble STEAP1 protein

Supplementary table S2. General information for patient-derived xenografts (PDXs).

PDXs	Patient	Disease status	Tumor site	Tumor mutations	Patient outcome
NBL50a	M/4 years	Relapsed	Liver metastasis	MYC-N (+), NF1 R1769*, TP53 C176F, LOH on 17p, 17q+, subclonal 4p- and 4q+	PD
Piro20Lung	M/1year	Relapsed	Lung metastasis	MYCN amplified, ALK F1245I, BCOR E1073*, BRAF V600E	PD
M37	F/28 years	Relapsed	Primary tumor	TP53 Y205C, NOTCH1 P2122L, NTRK3 L209I, RECQL4 R562W, RUNX1 L56S, ZFH3 S3177L, MDC1 H131N, TERT A202T, MDM4 V245A (highest allelic frequency among 21 mutations)	PD
OSOS1b	M/18years	Relapsed	Lung metastasis	TP53 A159P, INPP4A E940Q	PD
TEOS1c	M/18years	Relapsed	Lung metastasis	TP53 H168R, ATRX X2168_splice	PD
HGSOS05	M/24 years	Relapsed	Lung metastasis	TP53 H179L, EP300 C1164Y, SMAD2 W134, ERFF1 p94L, MDC1 P1801Q, SOX17 A166T, SUFU D159Y	PD
ES03a	M/32 years	Relapsed	Brain metastasis	EWS/FLI1 fusion positive	PD

PD, progressed disease

Supplementary table S3. Purity, affinity and endotoxin of GD2 Bispecific antibodies with varieties of platform.

Tumor antigen	Antibody	BsAb formats	Purity (%)	Binding affinity Kd (M)		Endotoxin (EU/mg)
			HPLC	CD3	Tumor antigen	
GD2	hu3F8	Monomeric BiTE	86	2.19E-08	1.10E-08	<2
GD2	hu3F8	Dimeric BiTE	99	1.84E-08	3.90E-08	<2
GD2	hu3F8	BiTE-Fc	92	4.53E-09	4.65E-09	<2
GD2	hu3F8	IgG-[L]-scFv	96	2.86E-09	3.61E-09	<2
GD2	hu3F8	IgG-H-scFv	99	2.70E-09	4.63E-09	<2
GD2	hu3F8	IgG-Heterodimer	98	4.97E-08	1.50E-08	<2
GD2	hu3F8	Chemical conjugate	ND	1.42E-09	ND	<2

Fig. S1. *In vivo* anti-tumor efficacy of T cells armed with a variety of GD2-BsAb platforms

(A) *In vivo* anti-tumor efficacy of GD2-BsAb armed T cells was tested in GD2(+) PDX mouse models. T cells were armed with various formats of GD2-BsAb including monomeric BiTE, dimeric BiTE, IgG heterodimer, BiTE-Fc, IgG-[H]-scFv, or IgG-[L]-scFv (2 μ g of each BsAb/ 2×10^7 cells) and administered twice weekly for 2 weeks, and their anti-tumor effect against neuroblastoma PDXs was compared among groups. This data has been partly published [14].

Fig. S2. *In vitro* cytokine analyses of EATs.

TH1 cell cytokines (IL-2, IL-6, IL-10, IFN- γ , and TNF- α) released by T cells were measured in each step of arming. (A) *In vitro* cytokine release of T cells after 20 minutes of incubation with increasing doses of GD2-BsAb. (B) *In vitro* cytokine levels were measured after 2 times of washing step. (C) *In vitro* cytokine release of T cells with increasing doses of GD2-BsAb after 4 hour-incubation with target cells (M14 melanoma cell line; effector to target ratio was 50:1). (D) *In vitro* cytokine release by EATs armed with increasing doses of GD2-BsAb after 4 hour-incubation with target cells (M14 melanoma cell line; effector to target ratio was 50:1).

Fig. S3. *In vivo* cytokine analyses of EATs.

(A) AUC for *in vivo* cytokine release was compared among groups. GD2-EAT (armed with 10 μ g of GD2-BsAb/2x10⁷ cells), GD2-BsAb (10 μ g) plus unarmed T cells (2x10⁷ cells), or unarmed T cells (2x10⁷ cells) were administered into GD2(+) osteosarcoma PDX bearing mice. *In vivo* cytokine levels were measured at different time points after treatment

Fig. S4. *In vivo* anti-tumor effect of autologous EATs

(A) Autologous patient's T cells (1×10^7 cells) were armed with GD2-BsAb (anti-GD2 IgG-[L]-scFv, 1 μ g) and iv administered twice a week for 2 weeks to corresponding patient's neuroblastoma PDXs bearing mice. Tumor response and changes of body weight were plotted.

Fig. S5. *In vivo* anti-tumor effect of GD2-EATs

(A) *In vivo* anti-tumor effect of GD2-EATs against a panel of human tumors including neuroblastoma PDXs, IMR32Luc neuroblastoma cell line xenografts, and M14Luc melanoma cell line xenografts. GD2-EATs (10 μ g of GD2-BsAb/2x10⁷ cells) were iv administered twice weekly for 2 to 3 weeks.

Fig. S6. *In vivo* anti-tumor effect of HER2-EATs

(A) *In vivo* anti-tumor effect of HER2-EATs against a panel of human tumors including telangiectatic osteosarcoma PDXs (TEOS1C), breast cancer PDXs (M37), and 143BLuc osteosarcoma cell line xenografts. HER2-EATs (10 μ g of HER2-BsAb/2 \times 10⁷ cells) were iv administered twice weekly for 2 to 3 weeks.

Fig. S7. *In vivo* anti-tumor effect of target antigen specific EATs

(A) *In vivo* anti-tumor activities of anti-STEAP1 (six transmembrane epithelial antigen prostate 1) EATs, anti-PSMA (prostate membrane antigen) EATs, and anti-EGFR (epidermal growth factor receptor) EATs were tested against each target antigen positive tumors. 2×10^7 of T cells were armed with 10 μ g of each BsAb and iv administered twice weekly for 2 to 3 weeks.

Fig. S8. Changes in body weight after EAT therapies.

(A) Changes in mouse body weight over times (body weight relative to that before treatment started) after treatment of GD2-EATs, HER2-EATs, STEAP1-EATs, PSMA-EATs, or EGFR-EATs.

Fig. S9. *In vivo* anti-tumor effect of high-dose BsAb.

(A) PBMCs and different doses of HER2-BsAb were administered iv into osteosarcoma cell line (143BLuc) xenografted mice, and anti-tumor response was compared among groups. (B) Effects of high-dose BsAb on T cell activation, exhaustion, and apoptosis. CD3(+) T cells were incubated with increasing concentrations of HER2-BsAb with or without target cells at 37°C for 4 hours and analyzed the expression of CD69, TIM-3, 7-AAD, and annexin-V by flow cytometry. HER2-EATs armed with increasing HER2-BsAb dose were incubated with or without target cells at 37°C for 4 hours and analyzed for expression of the same marker panel. The frequency of each marker-positive subpopulation was calculated after subtracting away that for the no-BsAb control.

Fig. S10. EAT cell number and *in vivo* anti-tumor efficacy of EATs.

(A) Anti-tumor effect by EAT cell number. At a fixed arming dose of 0.5 μ g of GD2-BsAb per 1x10⁶ of T cells, 5x10⁶ or 2x10⁷ of GD2-EATs were administered twice weekly for 2 weeks. Tumors were harvested on day 16 post treatment, and the frequencies of human CD45 (+) tumor infiltrating T cells were analyzed using flow cytometry.

Fig. S11. Total doses of HER2-EATs and *in vivo* anti-tumor effect

(A) Treatment schedule: Arm 1, HER-EATs (10 μ g of HER2-BsAb/2x10⁷ cells) were administered twice weekly for 1 week, and HER2-BsAb (10 μ g/dose) were followed twice weekly for 3 weeks; arm 2, 4 doses of HER2-EATs followed by 4 doses of HER2-BsAb; arm 3, 8 doses of HER2-EATs. (B) The effect of total number of HER2-EATs doses on long-term tumor control and survival.

Fig. S12. Target antigen escape after GD2-EAT treatment.

(A) GD2 staining of fresh frozen tumor sections. Osteosarcoma xenografted tumors were harvested after treatment and stained with mouse IgG3-3F8 antibody to stain GD2 antigens on tumors.

Fig. S13. Flow cytometry analysis of cryopreserved-thawed GD2-EATs.

(A) Cryopreserved-thawed GD2-EATs were analyzed for GD2-BsAb binding using anti-GD2-idiotype antibody. T cell subset (CD3, CD4, and CD8), apoptosis (Annexin-V), and T cell death (7AAD) were analyzed by flow cytometry and compared to freshly armed GD2-EATs. (B) CD4 and CD8 IHC staining of osteosarcoma PDXs treated with thawed GD2-EATs on day 28 post treatment.

Fig. S14. Flow cytometry analyses of $\gamma\delta$ T cells and CD3/CD28 bead expanded T cells

(A) Flow cytometry analyses of $\gamma\delta$ T cells and polyclonal T cells after expansion for 12 days.

Fig. S15. *In vivo* anti-tumor efficacy of $\gamma\delta$ -EATs supplemented by IL-2.

(A) *In vivo* anti-tumor activities of EATs were compared between $\gamma\delta$ T cells ($\gamma\delta$ -EATs) and $\alpha\beta$ T cells ($\alpha\beta$ -EATs) in osteosarcoma PDX mouse models. $\gamma\delta$ -GD2-EATs or $\gamma\delta$ -HER2-EATs (10 μ g of each BsAb/ 2×10^7 of $\gamma\delta$ T cells) were iv administered twice weekly for 2 weeks with supplemental ip zoledronate (3 μ g) and sc IL-2 (1,000IU). (B) Flow cytometry analyses of circulating human T cells and tumor infiltrating lymphocytes [CD45(+) and CD3(+) TILs] on day 7 and day 17 post treatment, respectively.

Fig. S16. *In vivo* anti-tumor efficacy of $\gamma\delta$ -EATs supplemented by IL-15 (IL15R α -IL15 complex).

(A) *In vivo* anti-tumor effect of $\gamma\delta$ -HER2-EATs supplemented by IL-2 or IL-15 in osteosarcoma PDX mouse models. $\gamma\delta$ -HER2-EATs (10 μ g of each BsAb/2x10⁷ of $\gamma\delta$ T cells) were iv administered twice weekly for 2 weeks with supplemental ip zoledronate (3 μ g) and sc IL-2 (1,000IU) or IL-15 (5 μ g). Anti-tumor response and changes of body weight were monitored. (B) IHC staining of tumors (HGSOC) treated with unarmed $\gamma\delta$ T cells plus zoledronate plus IL-15 (a), $\gamma\delta$ -GD2-EATs plus IL-2 (b), $\gamma\delta$ -GD2-EATs plus zoledronate (c), $\gamma\delta$ -GD2-EATs plus zoledronate plus IL-2 (d), $\gamma\delta$ -GD2-EATs plus IL-15 (e), $\gamma\delta$ -GD2-EATs plus zoledronate plus IL-15 (f) (x200). Tumors were harvested on day 16 post treatment.

Fig. S17. *In vivo* anti-tumor efficacy of thawed $\gamma\delta$ -EATs supplemented by IL-15 (IL15R α -IL15 complex).

(A) Thawed $\gamma\delta$ -STEAP1-EATs with supplementary IL-15 and zoledronate showed significant anti-tumor effect against STEAP1(+) Ewing sarcoma PDXs *in vivo* without toxicity. 2×10^7 of $\gamma\delta$ -T cells were armed with 10 μ g of STEAP1-BsAb and cryopreserved in liquid nitrogen. Thawed $\gamma\delta$ -STEAP1-EATs were administered twice a week for 3 weeks with supplementary IL-15 (5 μ g/dose, subcutaneously injected) and zoledronate (3 μ g/dose, intraperitoneally injected).

Fig. S1.

(A)






Fig. S2.


(A)



(B)



(C)



(D)




Fig. S3.

(A)




Fig. S4.

(A)




Fig. S5.

(A)




Fig. S6.

(A)




Fig. S7.

(A)




Fig. S8.




Fig. S9.




Fig. S10.

(A)





Fig. S11.

(A)



(B)






Fig. S12.

(A)

No treatment



Unarmed T cells



Relapsed tumors






Fig. S13.

(A)



(B)





Fig. S14.

(A) Gamma delta T cells



(B) Activated T cells




Fig. S15.





Fig. S16.



(B)




Fig. S17.

(A)

